MDLinxWomen Over 50 Lost 35% More Weight With This Surprising Combination

Postmenopausal women on menopausal hormone therapy lost 35% more weight on tirzepatide than those on tirzepatide alone after 12 months, in a Mayo Clinic observational cohort of 120 patients. Preclinical data suggest estrogen may enhance GLP-1 appetite suppression, though causality remains unconfirmed pending randomized trials.

Clinical Considerations

• The 35% weight loss difference is clinically striking but the observational, 120-patient design cannot establish causation — confounders including sleep quality, lifestyle engagement, and symptom burden likely contributed
• Estrogen may enhance GLP-1 receptor signaling, offering a biological mechanism beyond behavioral factors that warrants controlled investigation
• Up to 75% of postmenopausal women experience vasomotor symptoms; MHT-driven symptom relief may independently improve adherence to diet and activity changes
• Randomized trials are planned to assess whether MHT also amplifies cardiometabolic benefits of tirzepatide beyond weight loss alone

Action Items

• Review MHT eligibility in postmenopausal patients already on or starting tirzepatide, particularly those with vasomotor symptoms
• Counsel patients that this finding is hypothesis-generating, not practice-changing, and that MHT should not be initiated solely for weight loss
• Document MHT status when tracking GLP-1 treatment outcomes to contribute to emerging real-world evidence
• Monitor upcoming randomized trial data before adjusting combination therapy protocols

More in Postmenopausal Care